Premium
Kyverna Therapeutics Inc (KYTX)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin... Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. Show more
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX PR Newswire NEW YORK, Jan. 16...
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 13, 2025 Extending...
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan. 13, 2025 /PRNewswire/...
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX PR Newswire NEW YORK, Jan. 9, 2025...
SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets...
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 6, 2025 EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ -- Kyverna...
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX PR Newswire NEW YORK, Jan. 6, 2025...
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact The Gross Law Firm about pending Class Action - KYTX PR Newswire NEW YORK, Jan. 2, 2025 NEW YORK, Jan. 2, 2025...
February 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against KYTX PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.32 | -8.76712328767 | 3.65 | 3.67 | 3.24 | 298039 | 3.36622733 | CS |
| 4 | -0.48 | -12.5984251969 | 3.81 | 4.26 | 3.24 | 325090 | 3.76068302 | CS |
| 12 | -1.69 | -33.6653386454 | 5.02 | 7.2 | 3.24 | 321974 | 4.56562321 | CS |
| 26 | -7.53 | -69.3370165746 | 10.86 | 11.31 | 3.24 | 365400 | 5.93711943 | CS |
| 52 | -30.92 | -90.2773722628 | 34.25 | 35.01 | 3.24 | 448161 | 11.9377551 | CS |
| 156 | -30.92 | -90.2773722628 | 34.25 | 35.01 | 3.24 | 448161 | 11.9377551 | CS |
| 260 | -30.92 | -90.2773722628 | 34.25 | 35.01 | 3.24 | 448161 | 11.9377551 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
